Home / Investors / Business development

Business development

new platforms development
LIAISON XS
How it works

LIAISON XS, the new platform targeting small size laboratories launched in Europe in 2019, is planned to be launched in the U.S. in 2020 and in China in 2021.

Rationale
Penetrate a new market segment all over the world: Physician Office Labs in the U.S., Class I and II Hospitals in China and medium size hospitals in Europe to replace the older LIAISON platforms and to drive the conversion of clients using ELISA technology (e.g. Siemens, Qiagen) to CLIA.
Technology
Immunodiagnostics
Acquisitions
Siemens’ ELISA business portfolio acquisition
How it works

Acquisition of a product portfolio based on the ELISA immunodiagnostic technology from Siemens and access to Siemens' ELISA clients.

Rationale
Convert clients adopting Siemens’ ELISA products to our proprietary CLIA solutions, leveraging on the completeness of our CLIA menu and our LIAISON platforms.
Technology
Immunodiagnostics
Partnership
Distribution partnership with Beckman Coulter for Hepatitis and HIV tests in China
How it works

Commercialization in China of DiaSorin Hepatitis B, C and HIV tests on DiaSorin LIAISON XL LAS connected to Beckman Coulter’s leading automation solutions, the Power Express and Power Processor automated sample processing systems.

Rationale
Increase penetration in big hospitals in China via Hepatitis & Retroviruses panel.
Technology
Immunodiagnostics
Partnership
Distribution partnership with Beckman Coulter for Hepatitis and HIV tests in the U.S.
How it works

Agreement to provide a fully-automated solution (CLIA) for Hepatitis A, B, C and HIV tests in the U.S. on the LIAISON platforms. DiaSorin and Beckman Coulter are working together to get the approval from the Food and Drug Administration (FDA) to market these CLIA test in the U.S. territory.

Rationale
Launch of Hepatitis & Retroviruses panel in the U.S., leveraging on Beckman Coulter penetration in Large Labs and state-of-the-art technology tests by DiaSorin.
Technology
Immunodiagnostics
New products co-development
LIAISON QuantiFERON®-TB Gold Plus assay co-development with QIAGEN
How it works

Co-development of the new CLIA release of QuantiFERON®-TB Gold Plus diagnostic test available on the LIAISON family platforms.

Rationale
Accellerate the conversion of the global latent TB testing market to the modern blood-based QuantiFERON® test. LIAISON QuantiFERON®-TB Gold Plus assay, now available in Europe, will be launched in the U.S. by 2019 and China by 2020.
Technology
Immunodiagnostics

Impact on revenues

Impact on revenues